Not sure where he got the liquid funds to make any actual open brokerage account bet, but that is a story for another day. [Maybe he was, as is often the case. . . lying. Or perhaps the MSI.inu rug pull. Who knows? Who cares, really?]
In any event, the company is now over a year away for certain, from an FDA green-light under Hatch-Waxman, and it only won on one of the two patent battles it was waging.
Even so, from a high of over $11 a few weeks ago, to a low of about $4 early last week. . . it did rise on Friday, after some insiders bought small amounts of the company's shares (as the chart at right shows).
But -- whatever else may be said about this micro-cap, the horizon is well beyond where Martin ever trades. He usually is in and out in under three weeks -- often within days.
So it would not surprise me to learn that he bought some at around $4. . . and will dump it next week. . . at around $6 or $7.
Longer term, most big houses rate it an underweight / under-perform, due to the only potential drug product (called Yutrepia) now being over a year from FDA approval, at best -- even if it wins out on all the remaining patent appeals.
It also turns out that Watson Pharmaceuticals, a well-established generic, has the right by settlement agreement (see page 34 there), to enter on June 1, 2026 -- with its competing, and already green-lit generic alternative to Tyvaso (the branded), which will mean Yutrepia -- if approved, would only have about 11 months as the lone generic. . . then the floodgates open, and the prices will plummet, as Watson (the second generic) enters the US market.
So. . . it would be Condor's considered opinion, that Martin is riding along, in a pump and dump operation, perhaps even. . . along with management, of this intrepid company.
So it goes, and now you know. I had a hot cuppa', and some fresh dark Michigan cherries -- this quiet morning, and decided to take a bit of. . . a look.
Of course, do your own diligence.
नमस्ते
No comments:
Post a Comment